account_id none on file
legal_name Spruce Biosciences, Inc.
ticker SPRB
cik 1683553
domain sprucebio.com
linkedin_company_url https://www.linkedin.com/company/spruce-biosciences
entry_point_account_id none on file
name Spruce Biosciences Inc.
exchange Nasdaq
sector Health Care
sector index/company/sector/health-care/
calls 0 filings 8 executives 0 family 0
why_nownone on file
callsnone on file
filings
As of June 30, 2026, the total undiscounted lease payments for our non-cancelable operating lease for office space, which terminates in February 2028 unless renewed, was $0.6 million.
filing / Aug 12, 2026 / receipt
The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business.
filing / Aug 12, 2026 / receipt
In December 2022, the Company entered into a non-cancelable operating lease for approximately 6,500 square feet of office space in South San Francisco, California, which commenced in December 2022 and expires in February 2028 (the “South San Francisco Lease”).
filing / Aug 12, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.
filing / Aug 12, 2026 / receipt
As of March 31, 2026, the total undiscounted lease payments for our non-cancelable operating lease for office space, which terminates in February 2028 unless renewed, was $0.7 million.
filing / May 13, 2026 / receipt
The increased costs will decrease our net income or increase our net loss, and may require us to reduce costs in other areas of our business.
filing / May 13, 2026 / receipt
In December 2022, the Company entered into a non-cancelable operating lease for approximately 6,500 square feet of office space in South San Francisco, California, which commenced in December 2022 and expires in February 2028 (the “South San Francisco Lease”).
filing / May 13, 2026 / receipt
The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our product candidates, if approved.
filing / May 13, 2026 / receipt
executivesnone on file
familynone on file
upcoming
| 2026-11-09 | earnings call | scheduled | ir |
changesnone on file
mcp_package_hint
slug spruce-biosciences-inc
listing_url https://steadybase.io/company/data/index.json
mcp_url https://mcp.steadybase.io/mcp
steadybase-$